Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSR02-Fab-TF in Hepatocellular Carcinoma
NCT04601428Phase 1Terminated
- Sponsor
- Koo Foundation Sun Yat-Sen Cancer Center
- Start
- Jan 2021
- Primary completion
- Apr 2026
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSR02-Fab-TF in hepatocellular carcinoma (HCC), sponsored by Koo Foundation Sun Yat-Sen Cancer Center. Primary endpoints: Incidence and severity of adverse events at 50 days and HCC blood flow at 4 days. Started Jan 2021; status: terminated.
02
Drugs
CSR02-Fab-TF
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04601428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601428.